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Abstract Intermediates and ﬁnal products of protein
aggregation play crucial role in the development of
degenerative changes in a number of neurological diseases.
Pathological protein aggregation is currently regarded as
one of the most promising therapeutic targets for treatment
of these diseases. Transgenic mouse models of proteinop-
athies are an effective tool for screening and validation of
compounds, which can selectively affect metabolism of
aggregate-prone proteins. In this study, we assessed effects
of dimebon, a compound with known neuroprotective
properties, on a recently established transgenic mouse
model recapitulating key pathological features of amyo-
trophic lateral sclerosis (ALS) as the consequence of neu-
ron-speciﬁc overexpression of c-synuclein. Cohorts of
experimental transgenic mice received dimebon in drinking
water with this chronic treatment starting either before or
after the onset of clinical signs of pathology. We detected
statistically signiﬁcant improvement of motor performance
in a rotarod test in both dimebon-treated animal groups,
with more pronounced effect in a group that received
dimebon from an earlier age. We also revealed substan-
tially reduced number of amyloid inclusions, decreased
amount of insoluble c-synuclein species and a notable
amelioration of astrogliosis in the spinal cord of dimebon-
treated compared with control transgenic animals. How-
ever, dimebon did not prevent the loss of spinal motor
neurons in this model. Our results demonstrated that
chronic dimebon administration is able to slow down but
not halt progression of c-synucleinopathy and resulting
signs of pathology in transgenic animals, suggesting
potential therapeutic use of this drug for treatment of this
currently incurable disease.
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Introduction
A nonprescription drug dimebon used as an antihistamine
for more than two decades has recently attracted renewed
attention of both researchers and clinicians because of its
newly discovered effects on pathological processes asso-
ciated with neurodegenerative diseases and beneﬁts to
patients in several clinical trials. A promising results of
the Phase II clinical trials of dimebon in patients with
Alzheimer’s disease (Doody et al. 2008) and Huntington’s
disease (Kieburtz et al. 2010) inspired a number of studies
in various in vitro and animal models of molecular
pathologies, associated with neurodegeneration, as well as
continuation of clinical studies. Although preliminary and
yet formally published results of larger Phase III clinical
trial in patients with Alzheimer’s disease appear to be less
assuring than results of the Phase II trial, dimebon is still
considered as a promising therapeutic medicine for neu-
rodegenerative diseases, particularly in combination with
other drugs. For example, a clinical trial is currently under
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Arisept for treatment of Alzheimer’s disease.
Progress in clinical and pre-clinical studies of dimebon
is compromised by very vague understanding of the
mechanism of its action on the degenerating nervous sys-
tem. Various targets of dimebon have been suggested,
including mitochondrial defects (Bachurin et al. 2003;
Zhang et al. 2010; Naga and Geddes 2011), glutamate
toxicity (Grigorev et al. 2003; Lermontova et al. 2001),
serotonine receptors type 6 and 7 (Okun et al. 2010), and
other receprors and enzymes (Wu et al., 2008). There are
also evidence that dimebon enhances adult hippocampal
neurogenesis in mice (Pieper et al. 2010), and improves
learning and memory in neurotoxin-treated rats (Bachurin
et al. 2001) as well as working memory in rhesus monkeys
(Webster et al. 2011). However, these proposed mecha-
nisms cannot explain beneﬁcial effects of dimebon on such
clinically diverse conditions as Alzheimer’s and Hunting-
ton’s diseases. Yet, there is a common feature in patho-
genesis of these two neurodegenerative diseases as both are
proteinopathies (Skovronsky et al. 2006; Uversky 2009).
Pathological protein aggregation, formation of proteina-
ceous inclusions and consequent neuroinﬂamatory reaction
in affected regions of the nervous system are hallmarks of
these types of diseases, although clinical manifestations
vary from principally motor dysfunction in amyotrophic
lateral sclerosis (ALS) to essentially cognitive impairment
in Alzheimer’s disease or dementia with Lewy bodies.
Therefore, it was feasible to suggest that an important if not
the main target of dimebon in the degenerating nervous
system is protein aggregation with inclusion formation and/
or intraneuronal systems of aggregates clearance.
Several studies have demonstrated that dimebon indeed
can affect protein aggregation as well as associated path-
ological changes. The drug has been shown to reduce the
number of TDP-43 aggregates in SH-SY5Y cells express-
ing mutant forms of this protein and to increase extracel-
lular Ab levels in neuroblastoma cells, expressing mutant
APP (Yamashita et al. 2009; Steele et al. 2009). However,
in two studies that used TgCRND8 Alzheimer’s disease
mouse model, conﬂicting results have been reported on
dimebon ability to affect APP or oligomeric Ab levels
although the discrepancy was attributed to the differences
in drug dose and treatment duration (Steele et al. 2009;
Wang et al. 2011). The drug was not effective in a trans-
genic mouse model of a-synucleinopathy recapitulating
some features of early stage of Parkinson’s disease (Shel-
kovnikova et al. 2011). Therefore, available data describing
effects of dimebon on neuropathology mediated by protein
aggregation are sparse, contradictory, and need clarifying.
Here, we studied the effect of dimebon on protein
aggregation and its physiological consequences in a
mammalian model of proteinopathy transgenic mice with
pan-neuronal overexpression of an aggregate-prone protein
c-synuclein. These mice develop progressive pathology
characterized by accumulation of insoluble c-synuclein
species and amyloid inclusions in the nervous system,
neuroinﬂammation, selective cell loss of certain motor
neuron populations and selective axonal degeneration that
leads to the decline in motor function, paralysis and pre-
mature death (Ninkina et al. 2009). Altogether, pathology
in these mice recapitulates several key pathological fea-
tures of ALS (Ninkina et al. 2009 and manuscript sub-
mitted). Our data clearly demonstrated that chronic
administration of dimebon slowed progression of pathol-
ogy in this model, suggesting potential therapeutic use of
this drug for treatment of ALS and related proteinopathies.
Materials and Methods
Animals and Dimebon Treatment
A transgenic mouse line Thy1mcSN with high level of pan-
neuronal expression of c-synuclein and deposition of
pathological inclusions in the nervous system has been
described in our previous publication (Ninkina et al. 2009).
Transgenic males were housed one per cage with 12/12
light/dark cycle and free access to food and water.
Dimebon was purchased from NPO Organika (Nov-
okuznetsk, Russia). Two experimental groups of transgenic
mice received dimebon (10 lg/ml) in drinking water from
the age of 3 or 6 months. Control group of littermates
continued to receive normal water. All animal experiments
were carried out in accordance with the UK Animals
(Scientiﬁc Procedures) Act, 1986.
Motor Function Assessment
The motor performance of control and experimental
transgenic as well as wild-type mice was evaluated in
accelerating speed rotarod test at the age of 2, 4, 6, 9 and
12 months. Animals were trained on the UGO Basil rota-
rod (model 7560, Italy) for 5 min, using a constant speed
(8 rpm) mode. Later, on the same day each animal was
tested three times with 30-min breaks between the trials.
The mean of latency to fall for these three trials was
included in ﬁnal statistics.
RNA Expression Analysis
RNA was extracted from the thoracic section of spinal
cord, and the ﬁrst-strand cDNA synthesis and quantitative
RT-PCR were performed as described previously (Ninkina
et al. 2009). Primers 50-CCATGGACGTCTTCAAGAAA
GG-30 and 50-CGTTCTCCTTGGTTTTGGTG-30 were used
34 Neurotox Res (2012) 22:33–42
123to amplify c-synuclein cDNA. GAPDH mRNA (primers
50-CACTGAGCATCTCCCTCACA-30 and 50-GTGGGTGC
AGCGAACTTTAT-30) was used as the normalization
standard. Fold change was determined by 2-DDCT method
as described previously (Livak and Schmittgen 2001)u s i n g
StepOne v2.0 software.
Histological Analysis
Spinal cords of control and experimental animals were
collected, processed, embedded and stained with Congo
Red, or Cresyl Fast Violet (Nissle staining) or probed with
rabbit polyclonal antibody against GFAP (Sigma, USA,
1:500 dilution) as described previously (Robertson et al.
2004). Congo Red-positive aggregates were counted
within four randomly selected 50 lm 9 50 lm squares
(0.01 mm
2 in total) in the anterior horn region of 10–15
sections per animal, and the mean number of aggregates
per section for each animal was used for statistics. Total
number of motor neurons in the anterior horn region was
estimated on slides after Nissle staining using the cell
fractionator technique and presented as percent of wild-
type. All counts were performed by a person blind to the
origin of sections.
Protein Fractionation and Immunoblotting
Spinal cords were dissected and thoracic sections from
animals of each group were pooled. Samples were pro-
cessed as previously described (Giasson et al. 2002), with
minor modiﬁcations. In brief, after homogenization of tis-
sues in 10 volumes of ice-cold high salt (HS) buffer with
protease inhibitors (Complete Mini, Roche) and discarding
cell debris and nuclei by low-speed centrifugation, samples
were centrifuged at 100,000 g for 20 min at 4C. The
supernatant was recovered as HS fraction. The pellet was
washed in the same buffer and then re-extracted in HS
buffer containing 1% Triton X-100 (TX, or detergent-sol-
uble fraction), followed by high-speed centrifugation as
above. The ﬁnal pellet was resuspended and boiled in a gel-
loading buffer with 2% SDS, and designated as detergent-
insoluble or SDS fraction. All fractions were run on 16%
SDS-PAGE and transferred to PVDF membrane by semi-
dry blotting followed by blocking, incubation with anti-
bodies and detection procedure according to previously
established protocol (Buchman et al. 2002; Ninkina et al.
2003). Afﬁnity-puriﬁed rabbit polyclonal SK23 antibodies
(Buchman et al., 1998) were used in 1:500 dilution for
detection of c-synuclein. Mouse polyclonal antibody
against b-actin (Sigma) diluted 1:3,000 was used for nor-
malization of protein loading.
Statistical Analysis
Statistical analysis was performed using STATISTICA 6.0
software. Non-parametric Mann–Whitney U-test was
applied to assess differences between dimebon-treated and
control groups.
Results
Dimebon Increases Lifespan and Ameliorates Motor
Impairment in a Mouse Model of Synucleinopathy
Experimental mice received water solution, containing
10 lg/ml of dimebon, which allowed reaching an average
daily dose of *1.5 mg/kg, corresponding to the dose used
in clinical studies (Doody et al. 2008). Dimebon stability in
solutions has been properly addressed recently (Nirogi
et al. 2009), conﬁrming its good perseverance in water. As
has been shown by others (Giorgetti et al. 2010; Wang
et al. 2011), dimebon is completely eliminated from plasma
and brain within 6 h after administration of a single oral
dose but unlimited access to drinking solution in our study
ensured non-interrupted exposure to the drug and mainte-
nance of its pharmacologically relevant level in the nervous
system.
The age of onset for obvious clinical signs of pathology
in Thy1mcSN mice is around 6 month. The disease grad-
ually progresses leading to severe muscle weakness and
limb paralysis that result in rapid wasting. Mice usually
reach 1 year with only about 10% survive for more than
15 months. We assumed that experimental cohort with
early start of treatment will more likely to beneﬁt from
drug administration. To assess whether dimebon exerts
more pronounced effect when introduced at early, pre-
clinical stage, i.e., when accumulation of c-synuclein has
not yet resulted in obvious motor abnormalities, compared
with the early clinical stage, when locomotor impairment
can be already detected by instrumental tests, we employed
two mouse cohorts. Animals from the ﬁrst cohort received
dimebon in drinking water from the age of 3 months and
animals from the second group—from the age of 6 months.
Control groups of littermates received drinking water
without any additives.
Mouse motor function was assessed using accelerating
rotarod test before and at several time points after begin-
ning of drug administration. Animals from the ﬁrst exper-
imental cohort (early drug start) were tested at the age of 4,
6, 9 and 12 months, and animals from the second experi-
mental cohort (late drug start) at the age of 9 and
12 months. Statistically signiﬁcant improvement of animal
performance compared with non-treated controls was
achieved in both groups after 3 and 6 months of dimebon
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level of performance as wild-type mice (Fig. 1a). Notably,
mice in the group with late start of drug treatment signif-
icantly underperformed compared with mice that were
treated from the earlier age. Because the beneﬁcial effect of
the drug on the motor function was signiﬁcantly more
prominent for the latter group, our subsequent studies were
performed mostly with mice from this group.
To evaluate changes in the lifespan, we daily evaluated
conditions of mice in experimental and control groups to
detect either natural death or severe stage of wasting, when
they had to be culled to prevent further suffering. The
modest but statistically signiﬁcant increase in the lifespan
of transgenic mice treated with dimebon has been regis-
tered from the age of 3 months, comparing with untreated
mice. Occasionally, treated animals lived as long as
18 months (Fig. 1b).
Thus, using rotarod-assessed motor function and life-
span as end points, we demonstrated that chronic dimebon
administration in the used mouse model of proteinopathy
was beneﬁcial at both early and advanced stages of neu-
rodegeneration, with clear advantage of the early start of
the treatment.
Dimebon Reduces Inclusion Load and Affects
Aggregated c-Synuclein Levels In Vivo
Presence of proteinaceous inclusions in the nervous tissue
is a hallmark of advanced stage pathology in proteinopa-
thies (Skovronsky et al. 2006). There is no general con-
sensus about the role and hazardous potential for these
structures. Widely accepted current view is that they are
non-toxic and even protective in contrast to toxic soluble
oligomers (Bucciantini et al. 2002; Lashuel et al. 2002;
Caughey and Lansbury 2003), whereas there is clear evi-
dence of correlation between inclusion load and disease
stage (Thal et al. 2002). In Thy1mcSN transgenic mice,
multiple amyloid inclusions of various size can be detected
throughout the nervous system, and the number of inclu-
sions in the spinal cord directly correlates with the severity
of motor impairment (Ninkina et al. 2009). We assessed the
number of pathological inclusions, revealed by Congo Red
staining, which selectively detect amyloid structures, in the
anterior horn area of the spinal cord sections from dime-
bon-treated and control transgenic animals. Signiﬁcantly
lesser number of inclusions was detected in treated animals
(Fig. 2). Although the difference between two dimebon-
treated groups was not statistically signiﬁcant, the trend of
more pronounced decrease in inclusion numbers in the
group with early introduction to the drug was obvious (41.2
vs. 27.5% decrease), which is consistent with the results of
rotarod performance of these animals.
To conﬁrm observed effect of dimebon on accumulation
of insoluble ﬁbrillar c-synuclein species by an alternative
method, we used sequential fractionation of spinal cord
proteins with buffers of different detergent composition.
The presence of abundant aggregated c-synuclein species
in a detergent-insoluble fraction of the spinal cord of
Thy1mcSN mice has been shown previously (Ninkina et al.
2009). Five samples of thoracic spinal cords were pooled
for a group of 12-month-old mice treated with dimebon
from the age of 3 months and ﬁve samples—for a group of
age-matching control mice. Proteins were extracted from
these pooled ‘‘averaged’’ samples by extraction/ultra-
centrifugation as described in Materials and Methods.
Resulting salt-soluble (high salt, HS), detergent-soluble
Fig. 1 Lifespan and motor performance of control and dimebon-
treated c-synuclein transgenic mice. Thy1mcSN transgenic mice (TG)
were tested on accelerating rotarod after 3 and 6 months of drug
administration in both dimebon-treated groups, and additionally after
9 months in the group with an early start of treatment. Line graphs
show means ± SEM of latency to fall from the rotarod (a).
Statistically signiﬁcant differences between the control group of
transgenic animals and each of the treated groups (*P\0.05,
**P\0.01) as well as between dimebon-treated groups (
#P\0.05)
were detected at all time points. b Kaplan–Meier survival analysis of
dimebon-treated and control Thy1mcSN transgenic mice demon-
strates increased survival in the group that received dimebon from the
age of 3 months. In both panels, results for wild-type animals (WT)
animals are given for reference
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analysed by gel electrophoresis and immunoblotting with
antibodies against mouse c-synuclein. We detected a sub-
stantial decrease in both monomeric and high molecular
weight c-synuclein species in detergent-insoluble fraction
extracted from tissues of dimebon-treated compared with
control transgenic mice, while the levels of salt-soluble
(HS) and detergent-soluble (TX) forms were not essentially
affected (Fig. 3). This effect was not because of reduced
transgene expression in the drug-treated mice because
quantitative RT-PCR analysis revealed no differences in
spinal cord c-synuclein mRNA levels between two groups
of animals (data not shown).
Dimebon Treatment Alleviates Neuroinﬂammation
Chronic neuroinﬂammation characterized by appearance
of activated microglial and astroglial cells in affected
regions of the nervous system plays one of the central
roles in the progression of neurodegeneration (Glass
et al. 2010). Although dimebon has been originally
developed as an antihistamine, and therefore might
ameliorate inﬂammatory response in the degenerating
neural tissues, this effect of the drug has not been
assessed so far. In Thy1mcSN mice, the development of
motor pathology is accompanied by progressing neuro-
inﬂamation characterized by a marked activation of
astroglial cells in the spinal cord (Ninkina et al. 2009).
We compared the severity of reactive astrogliosis in the
spinal cord of dimebon-treated and control transgenic
mice. Considerable reduction in the number of activated
astrocytes revealed by immunostaining with antibody
against GFAP was observed in animals that received the
drug for 9 months (Fig. 4). Thus, reducing inﬂammatory
response may contribute to neuroprotective action of
dimebon.
Fig. 2 Dimebon treatment reduces the number of amyloid inclusions
in the spinal cord of c-synuclein transgenic mice. Representative
images of histological sections through the spinal cord of 12-month-
old control Thy1mcSN mice (a) and Thy1mcSN mice treated with
dimebon from the age of 3 months (b) stained for amyloid deposits
using Congo Red. Scale bar = 100 lm. The bar chart (c) shows
means ± SEM of the number of inclusions in the anterior horn of the
spinal cord. Statistically signiﬁcant difference between the control
and each experimental group (*P\0.05, Mann–Whitney U-test) as
well as total number of sections analysed per three animals for each
group are shown
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in the Spinal Cord of Thy1mcSN Mice
Another pathological feature typical to Thy1mcSN mice is
age-dependent loss of motor neurons in the spinal cord
(Ninkina et al. 2009). It was feasible to suggest that physio-
logical, behavioural and morphological improvements
observedindimebon-treatedgroupsoftransgenicmicemight
be because of the survival-promoting effect of this drug on
spinal motor neurons. To assess this, we stereologically
counted motor neurons in the anterior horns of the thorasic
spinal cord of the same animal cohorts that were used for
histological studies described above. Consistent with previ-
ously published data, signiﬁcant (*50%) reduction in the
number of motor neurons was revealed in Thy1mcSN com-
pared with age-matching wild-type mice. However, no dif-
ferenceinthenumberofmotorneuronswasobservedbetween
dimebon-treated and control transgenic animals (Fig. 5).
Discussion
Following ﬁrst reports demonstrating neuroprotective
activity of dimebon, studies of its mechanism of action
Fig. 3 Dimebon decreases amount of detergent-insoluble c-synuclein
species in the spinal cord of c-synuclein transgenic mice. Represen-
tative western blot of fractions obtained by sequential extraction of
proteins from the spinal cord of 12-month-old control Thy1mcSN
mice (-) and Thy1mcSN mice treated with dimebon from the age of
3 months (?) probed with an antibody against mouse c-synuclein is
shown. Proteins were extracted from pooled thoracic spinal cords of
ﬁve animals for each group. To detect low-abundant high molecular
weight c-synuclein species (upper panel), the membrane was exposed
for longer period than for detection of predominant monomeric form
of the protein (lower panel). HS high salt-soluble fraction, TX Triton-
X soluble fraction, and SDS detergent-insoluble fraction
Fig. 4 Dimebon treatment ameliorates astrocytosis in the spinal cord
of c-synuclein transgenic mice. Representative images of histological
sections through the spinal cord of 12-month-old control Thy1mcSN
mice (left panel) and Thy1mcSN mice treated with dimebon from the
age of 3 months (right panel) immunostained for reactive astroglia
marker GFAP. Scale bar = 50 lm
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primarily mitochondria, calcium metabolism and various
types of receptors. Recently, however, in response to
advances in our understanding of the nature of pathological
changes during neurodegeneration, the focus has shifted
towards less characterized targets, such as protein aggre-
gation (Yamashita et al. 2009; Steele et al. 2009; Wang
et al. 2011; Shelkovnikova et al. 2011). In this study, we
applied a mouse model of proteinopathy with well-deﬁned
and easily detected neurological pathology triggered by
overexpression of an amyloidogenic protein c-synuclein
(Ninkina et al. 2009), to investigate speciﬁc dimebon
effects on protein aggregation and its consequences to
animal physiology. This model, Thy1mcSN transgenic
mice, also recapitulates several key features of ALS
(Ninkina et al. 2009 and manuscript submitted), a pro-
teinopathy for which in vivo effects of dimebon have not
been so far tested. We employed two chronic dimebon
treatment regimens, starting either before the onset of
clinical signs of pathology or after animals become
symptomatic. Projected daily dose of the drug
corresponded to the dose used in clinical studies (Doody
et al. 2008). Groups of dimebon-treated and control ani-
mals were assessed for ﬁve parameters known to be sig-
niﬁcantly impeded in Thy1mcSN transgenic mice, namely,
the lifespan, the dynamics of motor function impairment,
aggregation/ﬁbrillation of c-synuclein, formation of amy-
loid inclusions and astrogliosis. Dimebon slightly increased
lifespan of Thy1mcSN mice but only when the treatment
started before the onset of obvious signs of pathology. This
was consistent with results of motor function analysis that
revealed better rotarod performance of Thy1mcSN mice
that received dimebon from the age of 3 months comparing
with mice that received the drug from the age of 6 months.
Although both dimebon-treated mouse groups performed in
this test better than control transgenic mice of the same
age, they were still substantially inferior to wild-type mice
and their ability to perform the task gradually declined.
Dimebon treatment also reduced the load of amyloid
inclusions in the spinal cord of Thy1mcSN mice with lar-
ger effect observed in a group of experimental animals
treated with the drug from the earlier age. Furthermore,
Fig. 5 The loss of spinal motor neurons in c-synuclein transgenic
mice is not affected by dimebon treatment. a Representative images
of Nissle-stained histological sections through the spinal cord of
12-month-old control wild-type (WT), Thy1mcSN mice (TG) and
Thy1mcSN mice treated with dimebon from the age of 3 months
(TG ? DIM). Scale bar = 30 lm. b The bar chart shows mean-
s ± SEM of the number of motor neurons in the anterior horn of the
spinal cord of 12-month-old control wild-type (WT), Thy1mcSN
transgenic mice (TG) and Thy1mcSN mice treated with dimebon from
the age of 3 months (three to four animals per group). Thy1mcSN
mice have signiﬁcantly less motor neurons than wild-type mice
(**P\0.01, Mann–Whitney U-test) but no signiﬁcant difference
between two groups of transgenic mice was found
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insoluble c-synuclein species in the spinal cord of these
animals. Taken together, these results suggest that dimebon
can slow down but not reverse pathological processes
triggered by overexpression of c-synuclein in the nervous
system of Thy1mcSN mice. This conclusion is sup-
ported by our observation that dimebon treatment alone
is not sufﬁcient to prevent the loss of motor neurons at
the advance stages of neurodegeneration in Thy1mcSN
mice.
The ability of dimebon to moderate protein aggregation
and decrease inclusion numbers was previously demon-
strated only in cultured cells overexpressing aggregation-
prone but non-amyloidogenic protein TDP-43. In that
experimental system, dimebon reduced the level of insol-
uble TDP-43 and the number of TDP-43-positive intra-
cellular inclusions (Yamashita et al. 2009). In contrast, in
animal studies, either no effect (Wang et al. 2011; Shel-
kovnikova et al. 2011) or promotion (Steele et al. 2009)o f
amyloidogenic proteins aggregation were reported. There-
fore, our study provides ﬁrst evidence that dimebon can
ameliorate pathological protein aggregation in vivo and
suggest that the effect of the drug is target-protein-depen-
dent or/and cell-type-speciﬁc.
The role of large amyloid inclusions in progression of
proteinopathies is a subject of heated debates. Although
these structures are clear and obvious histological hall-
marks of pathological protein aggregation and might
interfere with normal intraneuronal processes simply by
mechanical disruption of the cell infrastructure, there is
growing body of evidence that most toxic products of
protein aggregation are precursors of amyloid-forming
ﬁbrils, namely, protoﬁbrils and protein oligomers. Thus,
prevention of amyloid formation might be harmful to
affected neurons if it leads to increased concentration of
toxic precursor species. Yet the ability of the intracellular
clearance systems to dispose already formed amyloid
ﬁbrils (Rubinsztein 2006), particularly before they form
damagingly large inclusions, might make amyloidogenesis
beneﬁcial because it could swing the equilibrium of the
aggregation/ﬁbrillation process and as the result, reduce
intracellular concentration of the most toxic intermediate
products. Our observations suggest that dimebon might
affect clearance of amyloid inclusions formed by aggre-
gated c-synuclein, and further studies should reveal what
intracellular clearance system might be a target of this
drug.
Dimebon has been originally developed and used as an
antihistamine and therefore belongs to a group of drugs
with a well-known anti-inﬂammatory properties. These
agents act through multiple mechanisms, including recep-
tor-mediated and receptor-independent ones, as well as
affect migration of inﬂammatory cells (reviewed by Leurs
et al. 2002). It was therefore feasible to suggest that
dimebon might affect inﬂammatory processes in the
degenerated nervous system. Indeed, we noticed signiﬁ-
cantly reduced astrogliosis in the nervous system of the
drug-treated transgenic animals, suggesting that dimebon
might ameliorate neuroinﬂammation. Chronic neuroin-
ﬂammation plays one of the central roles in progression of
neurodegeneration (Glass et al. 2010). Inﬂammatory mol-
ecules and reactive oxygen species released by activated
glial cells contribute to neuron damage resulting in both
apoptotic death of certain neuronal populations and dys-
function of survived neurons. Neuroinﬂammatory response
may result in the damage of the blood–brain barrier,
exacerbating existing pathology through immune cells
inﬁltration into nervous tissues and further activation of
inﬂammatory cascades (Farina et al. 2007). Aggregated
proteins become able to cross the damaged blood–brain
barrier and trigger immune response by inducing autoan-
tibody production (Rowe et al. 1998; Orr et al. 2005;
Papachroni et al. 2007). Evidence for speciﬁc and impor-
tant role of activated astrocytes in neuronal dysfunction
in proteinopathies is rapidly accumulating (reviewed in
Allaman et al. 2011), and normalization of astrocytes func-
tion in degenerating nervous system is considered as a
promising approach for treatment of these diseases.
Pathological protein aggregation and neuroinﬂammation
can be regarded as universal drug targets in proteinopa-
thies, because in the majority of cases, they accompany
neurodegeneration and contribute to the development and/
or progression of neuronal dysfunction (Archer et al. 2011;
Glass et al. 2010). Taken together with the results of pre-
vious experimental and clinical studies, our data demon-
strated that dimebon treatment might be beneﬁcial at early
stages of the certain types of proteinopaties. Signiﬁcant
retardation of pathology progression in an animal model
that recapitulates key features of ALS suggests feasibility
and importance of further studies of dimebon as a potential
therapeutic drug for this devastating and currently com-
pletely incurable disease.
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